Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2).

What the trial testedas reported · 2026

No range given

−1.06percentage points

As reported

difference −1.06 %, no interval

the abstract, start to end

… placebo (estimated treatment difference, -1.06%; p < 0.001).

← favours treatmentfavours comparator →

could be chance

No interval given · direction only, strength unknown

Glycemic control

−1.06

Investigational compoundsGlycemic control

Investigational compounds × glycemic controlhelps?replicated

unlikelylikely

0.780.76 without it

← favours treatmentfavours comparator →

more certainless certain

1 / 5